EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Gil D Rabinovici iD, David S Knopman, Javier Arbizu, Tammie L S Benzinger, Kevin J Donohoe, Oskar Hansson, Peter Herscovitch, Phillip H Kuo, Jennifer H Lingler, Satoshi Minoshima, Melissa E Murray, Julie C Price und 4 weitere

Alzheimer's & Dementia · 2025-01 · 21 (1)

DOI: 10.1002/alz.14338 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Alzheimer's & Dementia, online erschienen am 08.01.2025. Verfasst von Gil D Rabinovici und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid, Brain, Molecular Imaging. Die Arbeit wurde bisher 152-mal zitiert (Crossref) und nennt 261 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand‐alone modalities. RESULTS For amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. Highlights A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloidBrainMolecular ImagingPositron-Emission Tomographytau ProteinsHumansNuclear MedicineSocieties, Medical

Stichwörter der Autor:innen

Alzheimer's diseasePET imagingamyloid PETappropriate use criteriabiomarkersbrain pathologyclinical carecognitive impairmentdementiadiagnosisearly detectionmemory disordersmolecular imagingneuroimagingneurology

Substanzen

Amyloidtau Proteins

Autor:innen und Institutionen

  • Department of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
  • Mayo Clinic Neurology and Neurosurgery, Rochester, Minnesota, USA.
  • Department of Nuclear Medicine, University of Navarra Clinic, Pamplona, Spain.
  • Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Nuclear Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Gil D Rabinovici

Zitieren

APA

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., Murray, M. E., Price, J. C., Salloway, S. P., Weber, C. J., Carrillo, M. C., & Johnson, K. A. (2025). Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer's & Dementia, 21(1). https://doi.org/10.1002/alz.14338

Vancouver

Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer's & Dementia. 2025;21(1). doi:10.1002/alz.14338

BibTeX
@article{Rabinovici2025,
  author = {Rabinovici, Gil D and Knopman, David S and Arbizu, Javier and Benzinger, Tammie L S and Donohoe, Kevin J and Hansson, Oskar and Herscovitch, Peter and Kuo, Phillip H and Lingler, Jennifer H and Minoshima, Satoshi and Murray, Melissa E and Price, Julie C and Salloway, Stephen P and Weber, Christopher J and Carrillo, Maria C and Johnson, Keith A},
  title = {Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {1},
  doi = {10.1002/alz.14338}
}
Kostenlos starten →